Jaguar Health Files Q2 2024 10-Q
Ticker: JAGX · Form: 10-Q · Filed: 2024-08-13T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
Related Tickers: JAGX
TL;DR
Jaguar Health's Q2 10-Q is in. Check financials.
AI Summary
Jaguar Health, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Key financial figures and operational details are included in the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Jaguar Health, Inc., crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Jaguar Health faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 20240813 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Jaguar Health, Inc. (company) — Filer of the 10-Q
- 20240630 (date) — End of the reporting period
- 20240813 (date) — Date of filing
- 2834 (number) — Standard Industrial Classification for Pharmaceutical Preparations
- 001-36714 (number) — SEC File Number
FAQ
What is the primary business of Jaguar Health, Inc. according to the SIC code?
According to the Standard Industrial Classification (SIC) code provided, Jaguar Health, Inc. is in the business of Pharmaceutical Preparations [2834].
What is the SEC file number for Jaguar Health, Inc.?
The SEC file number for Jaguar Health, Inc. is 001-36714.
When does the fiscal year for Jaguar Health, Inc. end?
The fiscal year for Jaguar Health, Inc. ends on December 31 (1231).
What was the former name of Jaguar Health, Inc.?
The former name of Jaguar Health, Inc. was Jaguar Animal Health, Inc., with a date of name change on 20130830.
What is the business address of Jaguar Health, Inc.?
The business address of Jaguar Health, Inc. is 200 PINE STREET SUITE 400, SAN FRANCISCO, CA 94104.
Filing Stats: 4,920 words · 20 min read · ~16 pages · Grade level 20 · Accepted 2024-08-13 06:45:45
Key Financial Figures
- $0.0001 — h registered: Common stock, Par Value $0.0001 Per Share JAGX The NASDAQ Capital M
Filing Documents
- jagx-20240630x10q.htm (10-Q) — 3810KB
- jagx-20240630xex31d1.htm (EX-31.1) — 11KB
- jagx-20240630xex31d2.htm (EX-31.2) — 11KB
- jagx-20240630xex32d1.htm (EX-32.1) — 7KB
- jagx-20240630xex32d2.htm (EX-32.2) — 7KB
- 0001558370-24-011971.txt ( ) — 16096KB
- jagx-20240630.xsd (EX-101.SCH) — 112KB
- jagx-20240630_cal.xml (EX-101.CAL) — 71KB
- jagx-20240630_def.xml (EX-101.DEF) — 514KB
- jagx-20240630_lab.xml (EX-101.LAB) — 813KB
- jagx-20240630_pre.xml (EX-101.PRE) — 694KB
- jagx-20240630x10q_htm.xml (XML) — 3147KB
— FINANCIAL INFORMATION
PART I. — FINANCIAL INFORMATION 1
Condensed Consolidated Financial Statements
Item 1. Condensed Consolidated Financial Statements 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements Of Operations 2 Condensed Consolidated Statements of Comprehensive Losses 3 Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 54
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 69
Controls and Procedures
Item 4. Controls and Procedures 69
— OTHER INFORMATION
PART II. — OTHER INFORMATION 71
Legal Proceedings
Item 1. Legal Proceedings 71
Risk Factors
Item 1A. Risk Factors 71
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 72
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities 72
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 72
Other Information
Item 5. Other Information 72
Exhibits
Item 6. Exhibits 73 SIGNATURE 74 Table of Contents
— FINANCIAL INFORMATION
PART I. — FINANCIAL INFORMATION
Condensed Consolidated Financial Statements
Item 1. Condensed Consolidated Financial Statements JAGUAR HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, (In thousands, except share and per share data) 2024 2023 (unaudited) Assets Current assets: Cash $ 16,049 $ 6,469 Accounts receivable, net 1,299 1,967 Other receivable 65 217 Inventory 9,556 9,189 Prepaid expenses and other current assets 13,142 10,121 Total current assets 40,111 27,963 Property and equipment, net 488 496 Operating lease - right-of-use asset 1,176 1,176 Intangible assets, net 19,408 20,116 Other assets 276 1,012 Total assets $ 61,459 $ 50,763 Liabilities, Redeemable preferred stock, and Stockholders' equity Current liabilities: Accounts payable $ 4,093 $ 4,974 Accrued liabilities 3,339 3,798 Deferred revenue 170 — Operating lease liability, current 416 348 Notes payable, net of discount (includes note designated at Fair Value Option amounting to $ 10.5 million as of June 30, 2024, and $ 0 December 31, 2023, respectively) 11,115 4,867 Total current liabilities 19,133 13,987 Operating lease liability, net of current portion 812 886 Deferred revenue - long term 638 — Notes payable, net of discount, net of current portion (includes notes designated at Fair Value Option amounting to $ 21.8 million as of June 30, 2024, and $ 31.0 million December 31, 2023, respectively) 21,813 30,993 Total liabilities 42,396 45,866 Commitments and contingencies (See Note 6) Redeemable preferred stock: $ 0.0001 par value; 179 and 0 shares designated from 10,000,000 preferred stock authorized at June 30, 2024, and December 31, 2023; 99 and 0 shares issued and outstanding at June 30, 2024 and December 31, 2023 2,485 — Stockholders' equity Series G convertible preferred stock: $ 0.0001 par value; 137 and 137 shares designated from 10,000,000 preferred stock authorized at June 30, 2024, and December